The United States campaign to reach herd immunity through vaccination involves a delicate — sometimes tricky — dance with side effects, public opinion and virus variants. All three are unpredictable, and can turn when you least expect it.
“It’s still a race between the variants and the vaccine,” Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security and a spokesman for the Infectious Diseases Society of America, told MarketWatch. All six cases of blood clots occurred in women ages 18 to 48. One woman died, and another remains in critical condition, according to details released by the FDA Tuesday. “We are recommending a pause in the use of this vaccine out of an abundance of caution,” health officials said.
“Knowing what I know now, I probably would not take the J&J,” he said. “I still think I would have taken the two-shot vaccines.” The latest complication has further delayed a rocky rollout in the European Union, which ordered approximately 200 million doses of the J&J vaccine in 2021. “We have made the decision to proactively delay the rollout of our vaccine in Europe,” J&J said in a statement Tuesday. The U.K. has ordered 30 million doses of the J&J vaccine, although it has not yet been authorized for use there. — Dr.
In one recent Kaiser Family Foundation poll taken before the J&J vaccination pause, 13% of Americans said they would definitely not get the vaccine, and 7% said they would get it only if required. The appeal of J&J and AstraZeneca The J&J blood-clot issue is similar to one that caused many European countries to pause and/or restrict use of the AstraZeneca AZN, -0.47% and Oxford University coronavirus vaccine, which is also an adenovirus viral vector-based vaccine. The U.K. has restricted its use to those over age 30.
“The J&J vaccine has kind of caught on because it’s one and done, so this pause will no doubt slow us down,” he said. “In our state, as we try to vaccinate more people in rural areas, we’ve run into real vaccine hesitancy or indifference to getting vaccinated.” “Herd immunity is likely something that will happen in late summer,” Adalja said. “We’re not going to get COVID zero — it’s going to be with us season after season, but it’s not going to have the ability to cause a public-health emergency. The key was to tame it, and the damage it was causing.”
More good news please(((
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.